Liquidia Corp
LQDANasdaq
$79.94
↑ +6.2%Jul 17 close · end-of-day
Price
1Y↑ +463.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$8.1B
Enterprise Value
$7.9B
P/E
470.2
P/S
28.1
P/B
74.4
EV/EBITDA
166.8
PEG
—
FCF Yield
0.5%
Dividend Yield
—
Revenue (TTM)
$288.1M
Net Income (TTM)
$22.3M
Free Cash Flow (TTM)
$41.1M
Gross Margin
—
Operating Margin
15.8%
Net Margin
7.7%
ROE
20.5%
ROIC
—
Debt / Equity
—
Net Cash
$222.8M
Return 1Y
+447.5%
Company profile
Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
- CEO
- Roger A. Jeffs
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- North Carolina
- Website
- liquidia.com
Management & directors
- Adair JasonChief Business Officer
- Boyle DanaChief Accounting Officer
- Jeffs RogerChief Executive Officer
- Kaseta MichaelCFO and COO
- Khindri SanjeevChief Development Officer
- Krepp SarahChief Human Resource Officer
- Moomaw ScottChief Commercial Officer
- Saggar RajeevChief Medical Officer
- Schundler RussellGeneral Counsel
Roles derived from SEC Form 4 filings.
Earnings
LQDA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$132.9M↑ +4158.5%
Diluted EPS$0.52↓ -215.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $739,628.00 | $12.9M | $15.9M | $17.5M | $14.0M | $158.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$59.1M | -$33.8M | -$38.8M | -$73.4M | -$121.3M | -$51.4M |
| Net income | -$59.8M | -$34.6M | -$41.0M | -$78.5M | -$130.4M | -$68.9M |
| Diluted EPS | -$1.76 | -$0.70 | -$0.67 | -$1.21 | -$1.63 | -$0.80 |
| Operating cash flow | -$54.1M | -$34.0M | -$28.6M | -$41.6M | -$93.4M | -$35.7M |
| Free cash flow | -$54.9M | -$34.1M | -$29.2M | -$42.9M | -$98.4M | -$40.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -7989.0% | -263.0% | -243.3% | -419.6% | -866.6% | -32.5% |
| Net margin | -8080.1% | -269.0% | -257.4% | -448.9% | -931.7% | -43.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7M | $4.4M | $2.9M | $3.1M | $8.8M | $54.3M | $92.0M | $132.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$27.2M | -$29.2M | -$36.1M | -$35.4M | -$37.5M | $1.8M | $19.8M | $61.5M |
| Net income | -$28.7M | -$31.0M | -$38.5M | -$38.4M | -$41.6M | -$3.5M | $14.6M | $52.9M |
| Diluted EPS | -$0.38 | -$0.40 | -$0.45 | -$0.45 | -$0.49 | -$0.04 | $0.18 | $0.52 |
| Operating cash flow | -$22.7M | -$25.1M | -$20.8M | -$30.7M | -$39.5M | -$9.8M | $44.2M | $53.0M |
| Free cash flow | -$24.0M | -$26.8M | -$22.1M | -$31.0M | -$40.5M | -$10.7M | $42.2M | $50.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -743.3% | -656.2% | -1237.8% | -1135.4% | -424.4% | 3.3% | 21.5% | 46.3% |
| Net margin | -783.5% | -697.6% | -1320.2% | -1229.7% | -470.5% | -6.5% | 15.8% | 39.8% |
Company news
Jul 20, 2026
Jul 16, 2026
Jul 15, 2026
- 5d agoSummit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Dealfinance.yahoo.com
- 5d agoDoes Liquidia (LQDA) Insider Selling Undercut Optimism Around YUTREPIA And Its Litigation Outlook?finance.yahoo.com
- 5d agoLiquidia (LQDA) Expands YUTREPIA As Patent Case Turns More Favorablefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | JEFFS ROGER· Chief Executive Officer | Sale | 32,744 | $71.52 | $2.3M | filing |
| 2026-07-13 | Kaseta Michael· CFO and COO | Sale | 18,977 | $71.52 | $1.4M | filing |
| 2026-07-13 | Schundler Russell· General Counsel | Sale | 13,692 | $71.52 | $979,251.84 | filing |
| 2026-07-13 | Saggar Rajeev· Chief Medical Officer | Sale | 9,223 | $71.52 | $659,628.96 | filing |
| 2026-07-13 | Moomaw Scott· Chief Commercial Officer | Sale | 8,864 | $71.52 | $633,953.28 | filing |
| 2026-07-13 | Boyle Dana· Chief Accounting Officer | Sale | 8,361 | $71.52 | $597,978.72 | filing |
| 2026-07-13 | Krepp Sarah· Chief Human Resource Officer | Sale | 7,306 | $71.52 | $522,525.12 | filing |
| 2026-07-13 | Adair Jason· Chief Business Officer | Sale | 7,301 | $71.52 | $522,167.52 | filing |
| 2026-07-13 | JEFFS ROGER· Chief Executive Officer | Sale | 2,505 | $71.39 | $178,831.95 | filing |
| 2026-07-13 | Kaseta Michael· CFO and COO | Sale | 1,453 | $71.39 | $103,729.67 | filing |
| 2026-07-13 | Khindri Sanjeev· Chief Development Officer | Sale | 1,101 | $71.52 | $78,743.52 | filing |
| 2026-07-13 | Schundler Russell· General Counsel | Sale | 1,046 | $71.39 | $74,673.94 | filing |
| 2026-07-13 | Saggar Rajeev· Chief Medical Officer | Sale | 703 | $71.39 | $50,187.17 | filing |
| 2026-07-13 | Moomaw Scott· Chief Commercial Officer | Sale | 675 | $71.39 | $48,188.25 | filing |
| 2026-07-13 | Boyle Dana· Chief Accounting Officer | Sale | 641 | $71.39 | $45,760.99 | filing |
| 2026-07-13 | Adair Jason· Chief Business Officer | Sale | 562 | $71.39 | $40,121.18 | filing |
| 2026-07-13 | Krepp Sarah· Chief Human Resource Officer | Sale | 558 | $71.39 | $39,835.62 | filing |
| 2026-07-13 | Khindri Sanjeev· Chief Development Officer | Sale | 84 | $71.39 | $5,996.76 | filing |
| 2026-07-10 | Krepp Sarah· Chief Human Resource Officer | Option exercise | 3,179 | — | — | filing |
| 2026-07-10 | Kaseta Michael· CFO and COO | Option exercise | 5,829 | — | — | filing |
| 2026-07-10 | Kaseta Michael· CFO and COO | Option exercise | 7,050 | — | — | filing |
| 2026-07-10 | JEFFS ROGER· Chief Executive Officer | Option exercise | 13,834 | — | — | filing |
| 2026-07-10 | JEFFS ROGER· Chief Executive Officer | Option exercise | 14,333 | — | — | filing |
| 2026-07-10 | Adair Jason· Chief Business Officer | Option exercise | 3,907 | — | — | filing |
| 2026-07-10 | Adair Jason· Chief Business Officer | Option exercise | 2,475 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.